Eli Lilly & Co. and Anima Biotech have teamed to develop small-molecule translation inhibitors for undisclosed protein targets. In exchange for a $30 million up-front fee and $14 million in research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results